Abbreviation: AraC, 1-β-D-arabinofuranosylcytosine; AML, acute myeloid leukemia; ALDH1A2, aldehyde dehydrogenase 1 family member A2.
Chemotherapy has been very useful in the treatment of leukemia. However, cellular drug resistance is the greatest impediment to successful treatment. The mechanism of drug resistance can roughly be divided into two processes: drug uptake or metabolism, and inhibition of apoptotic cell death or increased repair of drug-induced DNA damage [1, 2] .
Cytosine arabinoside (1-β-D-arabinofuranosylcytosine, AraC) is one of the most effective drugs in the chemotherapeutic treatment of acute myeloid leukemia (AML) [3] .
AraC is also active against other hematologic malignancies such as acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma [4] . Laboratory investigations to elucidate the biochemical correlation between drug action and drug resistance mechanisms have extensively examined the clinical importance of AraC, in order to obtain leads for the development of better therapeutic strategies.
AraC is converted into its active metabolite, cytosine arabinoside triphosphate (Ara-CTP), intracellularly in leukemic blasts by deoxycytidine kinase (dCK) [5] .
Ara-CTP is generally considered to be the active form of the drug since it both inhibits DNA polymerase and leads to AraC incorporation into DNA [6] . AraC is catabolized to 5 the non-toxic metabolite, arabinosideuridine (AraU), by a rapid deamination mediated by cytidine deaminase (CDD) [7, 8] . Various biochemical mechanisms of AraC resistance have been shown in experimental animal tumor models or in vitro systems [9] .
Low AraC phosphorylation or low dCK in marrow blasts has been associated with poor response [10] . It has also been reported that AraC resistance is induced when the influx of AraC is reduced because of the human equilibrative nucleoside transporter 1 (hENT1) [11] , when the degradation of AraC is enhanced or when there is excessive conversion of AraC to inactive AraU due to high levels of CDD [12] . Although multidrug resistance (MDR1) gene and multidrug resistance-associated protein (MRP) gene are commonly involved in drug resistance, both the genes have not been observed in AraC resistant cells [13] . Various studies have been performed to elucidate the mechanism of AraC resistance, but it still remains unexplained.
Therefore, the present study aimed at investigating the expression of proteins associated with the acquisition of resistance to AraC. The expression of the proteins was examined using two-dimensional fluorescence difference gel electrophoresis (2D-DIGE) in AraC-sensitive (K562S) and AraC-resistant (K562AC) cell lines derived from K562.
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Materials and Methods
Cell Culture
Human leukemia cell lines, K562S and K562AC, were obtained from the School of Medicine, Tohoku University. The resistant clones, termed K562/AC, were established and grown for 3 months, during which they were continuously exposed to increasing concentrations of Ara-C up to 50 mM, and were maintained in medium containing Ara-C. K562AC cells were established before, as described by Funato et al [13] .
K562S cells were confirmed to be sensitive to AraC and K562AC cells were confirmed to be resistant to Ara-C (Nihon Shinyaku Co., Japan). The cells were grown in RPMI-1640 medium (Nissui Pharmaceutical Co., Japan) with 10% fetal calf serum (Cellect, OH, USA) at 37°C in 5% CO 2 . Doxorubicin resistant derivative of K562 cell line was obtained from JCRB Japan, and maintained in medium containing Doxorubicin (Wako Co., Japan).
Cell Viability Assay
Cell viability was determined by the MTT assay method, using ALDH1A2 constructs and gene transfection.
We used RT-PCR to synthesize the full length cDNA for human ALDH1A2 (NM_170696). Total RNA was extracted from K562AC cells and used for the synthesis of the cDNAs. Full-length human ALDH1A2 cDNAs were subcloned into the N-terminus venus-tagged CAGGS expression vector. ALDH1A2 gene transfection to K562S cells was performed using Lipofectamine Plus (Invitrogen, Carlsbad, CA), following the manufacturer's instructions. To establish stable transfectants, transfected cells were selected by the medium containing 500 g/ml G418, and clones derived from single cells were picked up.
RNA Interference Experiments Using Small Interfering RNAs (siRNAs)
ALDH1A2 siRNA-1 (s16907) was purchased from Ambion (Life Technologies, Japan).
K562AC cells were transfected with siRNA using Lipofectamine Reagent (Life Technologies, Japan). As a negative control, a scrambled oligonucleotide, Negative control #2 (Life Technologies, Japan), was used. At 48 h after transfection, cells were treated with AraC for 24 h. Cell survival was determined using MTT assay, as described above.
Histopathology
Smeared bone marrow slides were fixed with 100% methanol. The slide was treated with 0.3% hydrogen peroxide to block nonspecific staining. The primary antibody used CR was defined according to Cheson's criteria [16] . Informed consent was obtained 12 according to the Declaration of Helsinki. The study protocol comprised a retrospective case series design that was approved by the institutional review board at Gifu university
hospital. Supplement Table 1 shows the main clinical findings of all the patients studied.
Statistical Analysis
The results depicted in Fig. 3 , Fig. 4 and Fig. 5 are expressed as means ± SD.
Statistically significant differences (p<0.05) between two groups were determined using Student's t-test.
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Results
The protein profiles by 2D-DIGE
Protein expression in K562S and K562AC cells was compared using 2D-DIGE.
AraC-resistance in K562 cells was established before, as described previously [13] . To confirm the resistance or sensitivity to AraC in K562S and K562AC cells, the viability of both cells after AraC treatment was examined using the MTT assay. After AraC treatment, there was no growth of K562S cells, while the proliferation of K562AC cells was unaffected. (Supplement Fig. 1 ).
In order to identify the proteins involved in the acquisition of AraC resistance, the differences in protein expression in K562S and K562A were examined by DIGE and mass spectrometry. The total number of differentially expressed proteins identified in the two cell lines was 2073. Of the proteins identified, the differences in expression of 15 proteins were found to be statistically significant (Fig. 1) . These proteins were identified by mass spectrometry. Table 1 shows a list of the differentially expressed proteins with their protein accession numbers, calculated fold changes, and p values.
The 15 proteins were assigned to four categories based on their function, namely macromolecular metabolism (amino acid and sugar metabolism), molecular cytoskeleton reorganization, signal transduction, and oxidative stress.
14 To validate the differential protein expression, RT-PCR and western blotting were performed for two proteins with the highest differential rate. The two proteins were found to be ALDH1A2 and vimentin (Fig. 2) .
Effects of ALDH1A2 on AraC resistance
It has recently been reported that the amount of expressed ALDH isoform correlates with drug resistance [17] [18]. And, some reports showed that retinoic acid inhibited the vimentin expression [19] . We examined the expression of vimentin in K562S treated with retinoic acid. The retinoic acid treatment decreased the vimentin expression (data not shown). This result suggested that vimentin expression was controlled by ALDH1A2 expression. Thus, RALDH2 expression was considered to be more important to acquire the resistance than vimentin expression. Therefore, the effect of ALDH1A2 on AraC resistance in K562AC cells was investigated here. This was done by knocking down ALDH1A2 in K562AC cells using siRNA. ALDH1A2 knock down (KD) was confirmed using RT-PCR and western blotting (Fig. 3A) . Cell viability was compared between the ALDH1A2 KD cells treated with and without AraC. The viability of ALDH1A2 KD cells was found to be reduced by AraC treatment. This shows that ALDH1A2 KD induces sensitivity to AraC in K562AC cells (Fig. 3B) . To confirm the effect of ALDH1A2 on AraC resistance, the ALDH1A2 gene was 15 transfected to K562AS cells. The cells with this transfection acquired the resistance to AraC (Fig. 4) .
Immunohistochemical analysis of ALDH1A2 in AraC-Resistant Patients
An in vitro study has suggested that ALDH1A2 may be associated with AraC resistance.
Therefore, the expression of ALDH1A2 in the peripheral blood of AraC-resistant patients was examined using immunohistochemical analysis. ALDH1A2 expression in AraC-resistant patients was compared before and after the acquisition of resistance. Fig.   5 shows that ALDH1A2 expression was high in patients with AraC resistance and that all patients had increased ALDH1A2 expression after the acquisition of AraC resistance.
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Discussion
The present study reveals that 15 proteins, including ALDH1A2, present in K562AC cells are significantly down-or up-regulated. ALDH1A2 belongs to the aldehyde dehydrogenase (ALDH) family. Twelve ALDH genes have been identified in humans.
These genes, located on different chromosomes, encode a group of enzymes which oxidize a variety of aliphatic and aromatic aldehydes [20, 21] . Many studies have shown that some ALDH family members play an important role in drug resistance [17, 18] .
ALDH3A1 (a member of the ALDH family) expression in tumor cells has been shown
to induce resistance to drug toxicity, resulting in a poor response to anti-tumor drugs. As previously reported, ALDH3A1 is associated with resistance to etoposide and Mitomycin C [18] . It is also known that transfection with rat ALDH3 confers oxazaphosphorine-specific resistance on human MCF-7 cells. The resistance is also known to be reversed upon pretreatment with diethylaminobenzaldehyde, an ALDH3
inhibitor [22] . It has also been previously reported that overexpression of ALDH1A2 induces drug resistance [17] .
ALDH1A2 is an enzyme that catalyzes the synthesis of retinoic acid from retinaldehyde. Retinoic acid is an active metabolite of vitamin A and regulates a wide range of biological processes including cell proliferation, differentiation, and morphogenesis [23] . Recently, Moreb et al showed that the overexpression of both ALDH1A2 and ALDH2 results in increased relative resistance to both 4-Hydroperoxycyclophosphamide (4-HC) and doxorubicin, but resistant mechanisms did not reveled [17] . We also examined the protein expression pattern in K562 
